Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Triple Negative Breast Neoplasms 2Neuroblastoma 2Melanoma 2Lung Neoplasms 2Gliosarcoma 2Glioblastoma 2Unilateral Breast Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Mesothelioma, Malignant 1Mesothelioma 1Locally Advanced Pancreatic Adenocarcinoma 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Inflammatory Breast Neoplasms 1Ganglioneuroblastoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

sargramostim 1montanide ISA 51 1itacitinib 1incomplete Freund's adjuvant 1Lenalidomide 1High-Throughput Screening Assays 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Plasma Cell × sargramostim × Clear all
NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Roswell Park Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡